pH 5.7 before sterilization. The mixture was subsequently incubated on a rotary shaker at 27 1C for 3 days. Seed culture (1 ml) was transferred into each of 10 Erlenmeyer flasks (500 ml) together with 100 ml of production medium containing potato dextrose broth (2.4%), malt extract (0.5%), Mg 3 (PO 4 ) 2 Á8H 2 O (0.5%) and agar (0.1%). The mixture was adjusted to pH 6.0 before sterilization. Fermentation was carried out on a rotary shaker at 27 1C for 3 days, followed by stationary culture for 10 days.
The culture broth (1.0 l) was added 1.0 l of EtOH. It was concentrated under reduced pressure after removing the mycelia by centrifugation and filtration. The resulting aqueous solution was extracted with EtOAc and the organic layer was concentrated to dryness in vacuo to afford a yellow solid (488 mg). It was applied to ODS column chromatography (eluted with 20, 40 and 60% aqueous CH 3 CN). The concentrated 20% CH 3 CN eluate (42.8 mg) was purified by HPLC (column, Pegasil ODS (20 fÂ250 mm, Senshu Scientific, Tokyo, Japan); mobile phase, 30% aqueous CH 3 CN; flow rate, 5.0 ml min À1 ; detection, UV at 210 nm). Pyrenocine B (3, 16.2 mg) and 1 (3.5 mg) were obtained at 16 and 18 min, respectively. The 40% CH 3 CN eluate (65 mg) was purified by HPLC (column, Pegasil ODS (20 fÂ250 mm); mobile phase, 40% aqueous CH 3 CN containing 0.1% TFA; flow rate, 5.0 ml min À1 ; detection, UV at 210 nm) to yield 15 mg of pyrenocine A (2). The 60% CH 3 CN eluate (70 mg) was also purified by HPLC (column, XBridge Prep C8 (10 fÂ250 mm, Waters, Milford, MA, USA); mobile phase, 32% aqueous CH 3 CN; flow rate, 3.0 ml min À1 ; detection, UV at 210 nm) to produce 9.9 mg of citreoviridin (4), which was identified by comparison of spectral data with published values. 9 Compound 1 O 4 ). The IR spectrum showed characteristic absorptions at 3431, 1697, 1633 and 1558 cm À1 , suggesting the presence of an hydroxy group and an a-pyrone ring. These physicochemical properties and 1 H and 13 C NMR spectra of 1 were similar to those of pyrenocines 6 (Table 1) . Compound 1 had the same 4-methoxy-6-methyl-a-pyrone as 2 and 3, as shown by comparison of the NMR spectra (Table 1) . However, the signal of 1¢-ketone of 2 and 3 was not observed in the 13 revealed that its side chain is a 3-hydroxy-1-butenyl group. HMBC study established the connection of C-1¢ of this side chain to C-5 of the a-pyrone ring (Figure 2) . Thus, the planar structure of the new pyrenocine analog, pyrenocine I (1), was deduced to be 5-[(1E)-3-hydroxy-1-butenyl]-4-methoxy-6-methyl-2H-pyran-2-one.
In vitro antitrypanosomal activity of 1-4 was evaluated using the GUTat 3.1 strain of Trypanosoma brucei brucei, by the method reported earlier. [3] [4] [5] Pyrenocine A (2) showed the most potent antitrypanosomal activity, with an IC 50 value of 0.12 mg ml À1 (Table 2 ). Pyrenocine I (1) had a similar antitrypanosomal activity (IC 50 ¼1.8 mg ml À1 ) to the commonly used drug suramin, although it was 10-fold less active than 2. However, among 1-3, 1 was the least cytotoxic against a human embryonic lung fibroblast cells, MRC-5 (Table 2) . Citreoviridin (4) exhibited antitrypanosomal activity of the same order as 2 and 3 (IC 50 ¼0.48 mg ml À1 ) but was less cytotoxic than both.
Although pyrenocines show several biological activities, reportedly being phytotoxic, antifungal, antibacterial, cytotoxic and antimalarial, [10] [11] [12] [13] there is hitherto no report of their antitrypanosomal activities. In the past, it has been reported that citreoviridin inhibited the mitochondrial F 1 -ATPase of Trypanosoma cruzi. 14 The structural similarity of citreoviridin and pyrenocines suggests that pyrenocines may effect their antitrypanosomal activity through a similar mode of action. 
